Inovio gets grant to partner with IVI and KNIH for Covid-19 vaccine

17th April 2020 (Last Updated April 17th, 2020 13:32)

Inovio Pharmaceuticals has received $6.9m in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to collaborate with the International Vaccine Institute (IVI) and the Korea National Institute of Health (KNIH) for a Covid-19 vaccine trial.

The alliance is for a Phase I/II trial of Inovio’s vaccine candidate, INO-4800, in South Korea. IVI will perform the trial in parallel with Inovio’s Phase I trial conducted in the US.

Read the full article here